Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apilimod in Crohn's Disease (SCORE)
NCT00138840Phase 2Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of apilimod in Crohn's disease (3 arms), sponsored by Synta Pharmaceuticals Corp. Primary endpoint: Proportion of patients achieving clinical remission and clinical response at Day 29. Started Aug 2005; status: completed.
02
Drugs
apilimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00138840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138840.